Dec 13,2019

Tandem Diabetes Care Announces FDA Clearance of the t:slim X2 Insulin Pump with Control-IQ Advanced Hybrid Closed-Loop Technology

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced U.S. Food and Drug Administration (FDA) clearance of the t:slim X2™ insulin pump with Control-IQ™ technology, an advanced hybrid-closed loop feature designed to help increase time in range (70-180 mg/dL), and the first system cleared to deliver automatic correction boluses in addition to adjusting insulin to help prevent high and low blood sugar.

REGULATORY FDA

#insulin pump

#closed loop

View Analyst & Ambassador Comments
Go to original news
Dec 17,2019

Medtronic Acquires Klue

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has completed the acquisition of Klue, a software company focused on behavior tracking that can provide real-time insights into when a person is consuming food. Klue’s technology is expected to be incorporated into the Medtronic Personalized Closed Loop (PCL) insulin pump system, currently in development.

COLLABORATION MERGERS & ACQUISITION

#product & service

#cgm

#closed loop

View Analyst & Ambassador Comments
Go to original news
Dec 17,2019

Nemaura Medical teams up with Changing Health to battle Type 2 diabetes in UK and Ireland

Nemaura Medical Inc (NASDAQ:NMRD), the maker of the SugarBEAT continuous glucose monitor, announced Tuesday it is teaming with Changing Health to improve the management, reversal and prevention of Type 2 diabetes starting in the UK and Ireland. The partnership will utilize daily glucose trend data provided by Nemaura’s non-invasive sugarBEAT monitor, combined with Changing Health’s evidence-based digital health coaching solution.

COLLABORATION PARTNERSHIP

#product & service

#cgm

#coaching

View Analyst & Ambassador Comments
Go to original news
Dec 18,2019

First Patients in Europe Start Using Insulet’s New Omnipod DASH™ Insulin Management System in the UK and the Netherlands

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced the launch of the new Omnipod DASH™ Insulin Management System (Omnipod DASH System) in the United Kingdom and the Netherlands. The tubeless Omnipod DASH System provides up to three days of non-stop insulin delivery, without the need for daily injections and allows individuals to discreetly and intuitively manage their diabetes via a new touchscreen interface allowing for greater freedom and flexibility to focus on living life to the fullest.

PRODUCT

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Dec 20,2019

Nemaura Provides 2019 Year-End Corporate Update

Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company commercializing sugarBEAT®, a non-invasive and flexible continuous glucose monitor (CGM), together with BEAT®diabetes, a health subscription service designed to help people with diabetes and prediabetes to better manage their condition through personalized lifestyle coaching, today provided a 2019 year-end corporate update.

#cgm

View Analyst & Ambassador Comments
Go to original news
Dec 20,2019

Insulet to Present at 38th Annual J.P. Morgan Healthcare Conference

Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced that management will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on January 14, 2020 at 11:00 a.m. (Pacific Time).

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Dec 20,2019

DarioHealth Announces Closing of $21.3 Million Private Placement

DarioHealth Corp. (Nasdaq: DRIO) ("DarioHealth" or the "Company"), a pioneer in the global digital therapeutics market, announced today that it has closed on a private placement of convertible preferred stock to institutional and private investors. The Company received aggregate gross proceeds of approximately $21.3 million, before deducting placement agent fees and other offering expenses payable by the Company.

FUNDING POST-IPO EQUITY
View Analyst & Ambassador Comments
Go to original news
Jan 11,2018

Rimidi appoints Josh Claman as CEO

Rimidi, a digital health company that provides software and clinical analytics for chronic disease management, today announced that it has appointed Austin-based Josh Claman as president and chief executive officer effective January 8, 2018. Dr. Lucienne M. Ide, Rimidi’s co-founder and current CEO, will continue to serve as chairman of Rimidi’s board of directors.

View Analyst & Ambassador Comments
Go to original news
Jan 02,2018

NYT, Bloomberg say Apple is working on Watch EKG, noninvasive glucose

Citing anonymous sources within Apple, reports in Bloomberg and the New York Times over the past weeks continue to add to the pile of leaks and rumors about two of Apple's currently under-development health devices: a wrist-worn glucose sensor and an EKG built into the Apple Watch. Combined with Apple's public efforts like the Stanford Heart study, previously documented conversations with the FDA, and participation in the FDA's pre-certification program, these efforts are starting to look like serious future products and features.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Jan 04,2018

Positive outcomes from WellDoc's BlueStar translate to cost savings, analysis finds

An analysis contracted by WellDoc found that the company’s digital therapeutic for Type 2 diabetes management could lead to an average savings of more than $250 per patient per month.

PRODUCT

#dtx

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES